№ lp_2_1_29049
File format: docx Character count: 8213 File size: 137 KB
Year: 2026
Region / City: United Kingdom
Theme: Pharmaceutical Treatment
Document Type: Prescribing Information
Organization: NHS
Author: Dr. Joanne Ritchie
Target Audience: Healthcare professionals, specifically specialists and GPs
Period of Validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Contraindications: Venous thromboembolic disorder, arterial thromboembolic disease, known thrombophilic disorders, known osteoporosis, headaches with focal neurological symptoms, pregnancy, breastfeeding
Monitoring: DEXA scan recommended after 1 year of treatment
Special Warnings/Precautions: Use of non-hormonal contraception for at least 1 month after initiation
Adverse Effects: Hot flushes, headache
Primary Care responsibilities for continuation: Prescribe as recommended, seek advice from the specialist if needed
Specialist Service responsibilities for initiation: Discuss benefits and side effects with the patient, initiate treatment and monitor
Criteria for Discontinuation: Menopause, increase in migraine frequency, ATE/VTE events, acute liver deterioration
Date of Initiation: Not specified
Communication: Contact details for the specialist and hospital pharmacy provided
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Changes have been made to this item. Details of the corrigendum are at the end of this document.5.18 RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE, Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg, Ryeqo®, Gedeon Richter Australia Pty Ltd.
Year: 2024
Region / City: Australia
Subject: Endometriosis treatment
Document Type: Medical submission
Organization: Gedeon Richter Australia Pty Ltd
Author: Gedeon Richter Australia Pty Ltd
Target Audience: Medical professionals, health authorities
Period of validity: Ongoing
Approval Date: 31 January 2024
Modification Date: Not specified
Topics: RICaDPrescribing Relugolix-estradiol-norethisterone Ryeqo